Friday 6-6-2014 Allergan Inc (AGN) $AGN opened at 164.87 hitting the high price of 166.12 and a day low of 164.19 with a total volume of 2,287,700. AGN had a previous close of 165.90 and has been seeing an average volume of 4,765,650.
Overall Average: 72% Buy
Recent stock forum discussions about AGN http://investorshangout.com/search?q=AGN&...mp;yt0=Go!
Curis Re-Initiates Dosing for CUDC-427 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 4:10PM CDT
Curis, Inc. (CRIS) announced that it has re-initiated dosing in the single-agent clinical trial on pipeline candidate, CUDC-427. (full story)
Pipeline Progress at GlaxoSmithKline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 10:26AM CDT
GlaxoSmithKline plc (GSK) recently announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. (full story)
Roche's Ventana Collaborates with AstraZeneca's MedImmune - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:57PM CDT
Roche's (RHHBY) Ventana Medical Systems, Inc. has entered into a collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)
Positive Data on Vertex Pharma's Kalydeco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 3:45PM CDT
Vertex Pharma (VRTX) announced positive results from a study on Kalydeco. (full story)
Shares of AGN Up 30.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 10:16AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 months, Allergan has returned 30.73% as of today's recent price of $164.67. (full story)
Global Facial Aesthetics Market to 2020 - In-Depth Analysis of the $5 Billion industry
M2 - Thu Jun 05, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqkxsc/facial_aesthetics) has announced the addition of the "Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets" report to their offering. The global facial aesthetics market was valued at $2.5 billion in 2013 and is forecast to reach $5.4 billion by 2020, at a CAGR of 11% Future growth will be driven by sustained economic recovery in developed countries such as the US, aided by increasing awareness among the general public of the facial injectables available to them. The focus of companies such as Allergan on Direct-to-Consumer (DTC) marketing has been effective in expanding patient demographics from exclusively wealthy individuals to a wider range of people. Individuals born during the 1980-1994 period present a significant opportunity for companies in this market to sustain revenue growth in the future as this demographic is seeking age reversal techniques earlier than their predecessors. Recurring revenue from facial injectables encourages beauty clinics and medical practitioners to continue to recommend facial injectables such as Botox and dermal fillers to their patients. Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets discusses the market, competitive landscape, and trends for two facial aesthetics market segments: Botox and dermal fillers. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes each segment's pipeline products and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Key geographies: US, Brazil, Germany, Turkey, France, Italy, Spain, Japan, China, India, Columbia and South Korea. - Information on market size for two facial aesthetics market segments: botox and dermal fillers. - Annualized market revenue data forecast to 2020 and company share data for 2013. - Qualitative analysis of key trends in the facial aesthetics market. - Information on the competitive landscape and the leading technologies of key players: Allergan, Galderma, Merz Pharma, Ipsen, Anteis, Valeant Pharmaceuticals International, Medytox, LIBP, Laboratoires Teoxane and Hugel. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Analyst Commentary 4 Global Facial Aesthetics Market: Device Overview 5 Global Facial Aesthetics Market: Market Characterization 6 Global Facial Aesthetics Market: Segment Analysis and Forecasts 7 Global Facial Aesthetics Market: Country Analysis and Forecasts 8 Global Facial Aesthetics Market: Competitive Landscape 9 Global Facial Aesthetics Market: Product Pipeline Analysis 10 Facial Aesthetics Market: Consolidation Landscape 11 Appendix For more information visit http://www.researchandmarkets.com/research/mq...aesthetics (full story)
Houston and New York Dermatologist Discusses Allergan's JUVEDERM VOLUMA XC and Volume Loss in the Cheeks
Marketwire - Thu Jun 05, 6:01AM CDT
Dr. Paul M. Friedman, a board-certified dermatologist in Houston and New York, has added JUVEDERM VOLUMA(TM) XC to his line of non-surgical injectable procedures. As the first and only U.S. Food and Drug Administration-approved filler for correcting age-related volume loss, JUVEDERM VOLUMA(TM) XC specifically restores fullness to the cheeks and midfacial area for patients age 21 and over. Dr. Friedman says he is pleased to offer patients the injectable gel treatment as another aesthetic option to help achieve a more youthful, refreshed appearance. (full story)
'Fast Money' Recap: How Real Is China's 'War of Words'?
at The Street - Thu Jun 05, 4:00AM CDT
The trading panel discussed whether Cisco, EMC or other companies tied to China will be affected. (full story)
Why Diamond Offshore Drilling Inc., Bristol-Meyers Squibb Company, and Allergan Inc. Are Today's 3 W
John Divine, The Motley Fool - Motley Fool - Wed Jun 04, 8:02PM CDT
It was a relatively unremarkable day on Wall Street today, a low-volume session that lacked astounding economic data or headline-making broad market swings. But beneath the stock market's calm surface, there was a healthy dose of chaos brewing -- a... (full story)
Gilead Unveils GS-9973 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:40AM CDT
Gilead (GILD) announced updated interim data on GS-9973 from an ongoing phase II study. (full story)
Bayer Looking to Expand Adempas Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:00AM CDT
Bayer (BAYRY) announced the initiation of a new study on its pulmonary hypertension drug, Adempas. (full story)
Acadia Healthcare Company (ACHC) CQH Soars: Stock Adds 14.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 8:18AM CDT
Acadia Healthcare Company, Inc. (ACHC) was a big mover last session, as the company saw its shares rise by over 14% on the day. (full story)
Wednesday’s Top Health Care Stories: Valeant, Allergan, UnitedHealth Group, and Cyberonics
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 04, 8:13AM CDT
Let's take a look at four stocks -- Valeant Pharmaceuticals , Allergan , UnitedHealth Group , and Cyberonics -- which could all loom large in health care headlines this Wednesday morning. Keep an eye on Valeant's bid for Allergan... (full story)
Everything You Need to Know About Valeant's Deal With Allergan
Mark Reeth and Michael Douglass, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Shares of pharmaceutical company Valeant have remained steady today despite the recent drama surrounding its acquisition of Allergan maker of Botox. According to Motley Fool analyst Michael Douglass, Valeant has been attempting to acquire... (full story)
Eli Lilly's Cyramza 'REVELs' in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 4:30PM CDT
Eli Lilly and Company's (LLY) Cyramza showed improved overall survival rate in NSCLC patients in a global phase III REVEL study. (full story)
Data on Bristol-Myers' Yervoy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 3:55PM CDT
Bristol-Myers (BMY) reported data on Yervoy from a phase III study. (full story)
Valeant Relentless on Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 1:02PM CDT
Valeant (VRX) has yet again increased its offer for Allergan (AGN). As per the latest offer, each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock. (full story)
Next Support Level for Allergan (AGN) is $167.26
Comtex SmarTrend(R) - Tue Jun 03, 10:15AM CDT
Shares of Allergan (AMEX:AGN) opened today below their pivot of $171.12 and have already reached the first level of support at $169.75. Should the shares continue to fall, the support pivots of $167.26 and $163.40 will be of interest. (full story)
Company News for June 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 9:06AM CDT
Companies in the News are: CONN,HCT,VTR,AGN,VRX,ARIA (full story)
Will This Analyst Downgrade Hurt Allergan (AGN) Stock Today? (Update)
at The Street - Tue Jun 03, 8:14AM CDT
Credit Suisse downgraded Allergan (AGN) to "neutral" from "outperform" and set a $190 price target. The firm noted risk/reward is balanced, following the latest bid from Valeant (VRX). (full story)
Overall Average: 72% Buy
Recent stock forum discussions about AGN http://investorshangout.com/search?q=AGN&...mp;yt0=Go!
Curis Re-Initiates Dosing for CUDC-427 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 4:10PM CDT
Curis, Inc. (CRIS) announced that it has re-initiated dosing in the single-agent clinical trial on pipeline candidate, CUDC-427. (full story)
Pipeline Progress at GlaxoSmithKline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 10:26AM CDT
GlaxoSmithKline plc (GSK) recently announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. (full story)
Roche's Ventana Collaborates with AstraZeneca's MedImmune - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:57PM CDT
Roche's (RHHBY) Ventana Medical Systems, Inc. has entered into a collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)
Positive Data on Vertex Pharma's Kalydeco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 3:45PM CDT
Vertex Pharma (VRTX) announced positive results from a study on Kalydeco. (full story)
Shares of AGN Up 30.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 10:16AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 months, Allergan has returned 30.73% as of today's recent price of $164.67. (full story)
Global Facial Aesthetics Market to 2020 - In-Depth Analysis of the $5 Billion industry
M2 - Thu Jun 05, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mqkxsc/facial_aesthetics) has announced the addition of the "Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets" report to their offering. The global facial aesthetics market was valued at $2.5 billion in 2013 and is forecast to reach $5.4 billion by 2020, at a CAGR of 11% Future growth will be driven by sustained economic recovery in developed countries such as the US, aided by increasing awareness among the general public of the facial injectables available to them. The focus of companies such as Allergan on Direct-to-Consumer (DTC) marketing has been effective in expanding patient demographics from exclusively wealthy individuals to a wider range of people. Individuals born during the 1980-1994 period present a significant opportunity for companies in this market to sustain revenue growth in the future as this demographic is seeking age reversal techniques earlier than their predecessors. Recurring revenue from facial injectables encourages beauty clinics and medical practitioners to continue to recommend facial injectables such as Botox and dermal fillers to their patients. Facial Aesthetics Market to 2020 - Economic Recovery Drives Growth in the US as Increasing Awareness Fuels Demand in Developing Markets discusses the market, competitive landscape, and trends for two facial aesthetics market segments: Botox and dermal fillers. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes each segment's pipeline products and gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Key geographies: US, Brazil, Germany, Turkey, France, Italy, Spain, Japan, China, India, Columbia and South Korea. - Information on market size for two facial aesthetics market segments: botox and dermal fillers. - Annualized market revenue data forecast to 2020 and company share data for 2013. - Qualitative analysis of key trends in the facial aesthetics market. - Information on the competitive landscape and the leading technologies of key players: Allergan, Galderma, Merz Pharma, Ipsen, Anteis, Valeant Pharmaceuticals International, Medytox, LIBP, Laboratoires Teoxane and Hugel. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Analyst Commentary 4 Global Facial Aesthetics Market: Device Overview 5 Global Facial Aesthetics Market: Market Characterization 6 Global Facial Aesthetics Market: Segment Analysis and Forecasts 7 Global Facial Aesthetics Market: Country Analysis and Forecasts 8 Global Facial Aesthetics Market: Competitive Landscape 9 Global Facial Aesthetics Market: Product Pipeline Analysis 10 Facial Aesthetics Market: Consolidation Landscape 11 Appendix For more information visit http://www.researchandmarkets.com/research/mq...aesthetics (full story)
Houston and New York Dermatologist Discusses Allergan's JUVEDERM VOLUMA XC and Volume Loss in the Cheeks
Marketwire - Thu Jun 05, 6:01AM CDT
Dr. Paul M. Friedman, a board-certified dermatologist in Houston and New York, has added JUVEDERM VOLUMA(TM) XC to his line of non-surgical injectable procedures. As the first and only U.S. Food and Drug Administration-approved filler for correcting age-related volume loss, JUVEDERM VOLUMA(TM) XC specifically restores fullness to the cheeks and midfacial area for patients age 21 and over. Dr. Friedman says he is pleased to offer patients the injectable gel treatment as another aesthetic option to help achieve a more youthful, refreshed appearance. (full story)
'Fast Money' Recap: How Real Is China's 'War of Words'?
at The Street - Thu Jun 05, 4:00AM CDT
The trading panel discussed whether Cisco, EMC or other companies tied to China will be affected. (full story)
Why Diamond Offshore Drilling Inc., Bristol-Meyers Squibb Company, and Allergan Inc. Are Today's 3 W
John Divine, The Motley Fool - Motley Fool - Wed Jun 04, 8:02PM CDT
It was a relatively unremarkable day on Wall Street today, a low-volume session that lacked astounding economic data or headline-making broad market swings. But beneath the stock market's calm surface, there was a healthy dose of chaos brewing -- a... (full story)
Gilead Unveils GS-9973 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:40AM CDT
Gilead (GILD) announced updated interim data on GS-9973 from an ongoing phase II study. (full story)
Bayer Looking to Expand Adempas Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 10:00AM CDT
Bayer (BAYRY) announced the initiation of a new study on its pulmonary hypertension drug, Adempas. (full story)
Acadia Healthcare Company (ACHC) CQH Soars: Stock Adds 14.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 8:18AM CDT
Acadia Healthcare Company, Inc. (ACHC) was a big mover last session, as the company saw its shares rise by over 14% on the day. (full story)
Wednesday’s Top Health Care Stories: Valeant, Allergan, UnitedHealth Group, and Cyberonics
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 04, 8:13AM CDT
Let's take a look at four stocks -- Valeant Pharmaceuticals , Allergan , UnitedHealth Group , and Cyberonics -- which could all loom large in health care headlines this Wednesday morning. Keep an eye on Valeant's bid for Allergan... (full story)
Everything You Need to Know About Valeant's Deal With Allergan
Mark Reeth and Michael Douglass, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Shares of pharmaceutical company Valeant have remained steady today despite the recent drama surrounding its acquisition of Allergan maker of Botox. According to Motley Fool analyst Michael Douglass, Valeant has been attempting to acquire... (full story)
Eli Lilly's Cyramza 'REVELs' in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 4:30PM CDT
Eli Lilly and Company's (LLY) Cyramza showed improved overall survival rate in NSCLC patients in a global phase III REVEL study. (full story)
Data on Bristol-Myers' Yervoy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 3:55PM CDT
Bristol-Myers (BMY) reported data on Yervoy from a phase III study. (full story)
Valeant Relentless on Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 1:02PM CDT
Valeant (VRX) has yet again increased its offer for Allergan (AGN). As per the latest offer, each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock. (full story)
Next Support Level for Allergan (AGN) is $167.26
Comtex SmarTrend(R) - Tue Jun 03, 10:15AM CDT
Shares of Allergan (AMEX:AGN) opened today below their pivot of $171.12 and have already reached the first level of support at $169.75. Should the shares continue to fall, the support pivots of $167.26 and $163.40 will be of interest. (full story)
Company News for June 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Jun 03, 9:06AM CDT
Companies in the News are: CONN,HCT,VTR,AGN,VRX,ARIA (full story)
Will This Analyst Downgrade Hurt Allergan (AGN) Stock Today? (Update)
at The Street - Tue Jun 03, 8:14AM CDT
Credit Suisse downgraded Allergan (AGN) to "neutral" from "outperform" and set a $190 price target. The firm noted risk/reward is balanced, following the latest bid from Valeant (VRX). (full story)
